State Rep. Melanie Miller toured Heffelfinger’s Meats in Jeromesville as Ohio rolls out $14 million for meat‑processing grants. The third‑generation plant previously used a 2022 award to buy a backup generator.

The SEC says a Dallas hotel‑fund manager raised about $86M by overstating hotel ownership and recycling investor capital into payouts.

An L.A. jury found Johnson & Johnson not negligent in a talc-related ovarian cancer suit brought by three families, adding another twist to the sprawling litigation.

Lowe's has applied to annex about 16.8 acres on Shelbyville Pike for a second Murfreesboro store, putting traffic and stormwater squarely in the spotlight.

A family-restored mini-golf course, a frontier-inspired cafe and a joint restaurant are set to open in Townsend this summer.

Amerimed Emergency Medical Services filed for Chapter 11 in Atlanta while former employees allege the company skipped the WARN Act notice. The move adds legal and operational uncertainty for staff and local partners.

Staff at two Granny’s Kitchen locations in Oklahoma City say paychecks never arrived after abrupt closures; the franchisor says it is investigating.

Unionized staff at Marriott Marquis Houston ratified a contract that raises pay to $22 by 2028, adds Juneteenth as a paid holiday and lowers healthcare costs.

A Delaware magistrate ordered Paramount to produce informal board emails tied to its 2025 Skydance merger, giving investors a partial look at internal deliberations.

An Austin medical‑cannabis company sued several hemp sellers, alleging lab tests show many products contain marijuana‑level THC and contaminants.

Regulatory filings show Google will pay SpaceX about $920 million a month for access to tens of thousands of Nvidia GPUs. The deal runs Oct 2026–Jun 2029 and includes delivery and exit clauses.

Mobb Deep co‑founder Havoc opens The Bridge dispensary in Astoria this weekend, pairing DJs and product samplings with a social‑equity partnership.

A Manhattan judge allowed a class-action accusing Abbott’s PediaSure of overstating its “clinically proven” growth benefits to proceed, citing packaging and ads that could imply height gains.